In contrast to most previous studies, we revealed TP53-MUT characteristic in NSCLC patients according to histology-specific differences and the association between TP53-MUT and the mutation landscape, the TMB, and the OS. These findings suggest a need for individualized management for patients with LUAD and LUSC who carry a TP53-MUT, and warrant further research.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: